Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Ganirelix may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Ganirelix

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Ganirelix Gedeon Richter contains the active substance ganirelix and belongs to a group of medicines called "antigonadotropin-releasing hormones" which act against the actions of the natural gonadotropin-releasing hormone (GnRH). GnRH regulates the release of gonadotropins (luteinising hormone (LH) and follicle stimulating hormone (FSH)). Gonadotropins play an important role in human fertility and reproduction. In women, FSH is needed for the growth and development of follicles in the ovaries. Follicles are small round sacs that contain the egg cells. LH is needed to release the mature egg cells from the follicles and ovaries (i.e. ovulation). Ganirelix Gedeon Richter inhibits the action of GnRH, resulting in suppression of the release of especially LH. Ganirelix Gedeon Richter is used for In women undergoing assisted reproduction techniques, including in vitro fertilisation (IVF) and other methods, occasionally ovulation may occur too early causing a significant reduction in the chance of getting pregnant. Ganirelix Gedeon Richter is used to prevent the premature LH surge that might cause such a premature release of egg cells. In clinical studies ganirelix was used with recombinant follicle stimulating hormone (FSH) or corifollitropin alfa, a follicle stimulant with a long duration of action.

2.

What you need to know before you take it

e Ganirelix Gedeon Richter

Do not use Ganirelix Gedeon Richter if you are allergic to ganirelix or any of the other ingredients of this medicine (listed in section 6); if you are hypersensitive to gonadotropin-releasing hormone (GnRH) or a GnRH analogue; if you have a moderate or severe kidney or liver disease; if you are pregnant or breast-feeding. Warnings and precautions Talk to your doctor, pharmacist or nurse before using Ganirelix Gedeon Richter.

1

Allergic reactions If you have an active allergic condition, please tell your doctor. Your doctor will decide, depending on the severity, if additional monitoring is required during treatment. Cases of allergic reactions have been reported, as early as with the first dose. Allergic reactions, both generalised and local, including hives (urticaria), swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing and/or swallowing (angioedema and/or anaphylaxis) have been reported (see also section 4). If you have an allergic reaction, stop using Ganirelix Gedeon Richter and seek immediate medical assistance. Ovarian hyperstimulation syndrome (OHSS) During or following hormonal stimulation of the ovaries, ovarian hyperstimulation syndrome may develop. This syndrome is related to the stimulation procedure with gonadotropins. Please refer to the package leaflet of the gonadotropin-containing medicine prescribed for you. Multiple births or birth defects The incidence of congenital malformations after assisted reproduction techniques may be slightly higher than after spontaneous conceptions. This slightly higher incidence is thought to be related to characteristics of the patients undergoing fertility treatment (e.g. age of the woman, sperm characteristics) and to the higher incidence of multiple gestations after assisted reproduction techniques. The incidence of congenital malformations after assisted reproduction techniques using ganirelix is not different from that after using other GnRH analogues in the course of assisted reproduction techniques. Pregnancy complications There is a slightly increased risk of pregnancy outside of the uterus (an ectopic pregnancy) in women with damaged fallopian tubes. Women weighing less than 50 kg or more than 90 kg The efficacy and safety of ganirelix has not been established in women weighing less than 50 kg or more than 90 kg. Ask your doctor for further information. Children and adolescents There is no relevant use of Ganirelix Gedeon Richter in children or adolescents. Other medicines and Ganirelix Gedeon Richter Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Pregnancy, breast-feeding and fertility Ganirelix Gedeon Richter should be used during controlled ovarian stimulation for assisted reproduction techniques (ART). Do not use Ganirelix Gedeon Richter during pregnancy and breast-feeding. Ask your doctor or pharmacist for advice before using this medicine. Driving and using machines The effects of Ganirelix Gedeon Richter on ability to drive and use machines have not been studied. Ganirelix Gedeon Richter contains sodium This medicine contains less than 1 mmol sodium (23 mg) per injection, that is to say essentially 'sodium-free'.

3.

How to take it

Ganirelix Gedeon Richter

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

2

Ganirelix Gedeon Richter is used as part of the treatment for assisted reproduction techniques (ART) including in vitro fertilisation (IVF). Ovarian stimulation with follicle stimulating hormone (FSH) or corifollitropin may start at day 2 or 3 of your period. Ganirelix Gedeon Richter (0.25 mg) should be injected into the fatty layer just under the skin once daily, starting on day 5 or day 6 of stimulation. Based on your ovarian response, your doctor may decide to start on another day. Ganirelix Gedeon Richter and FSH should be administered approximately at the same time. However, these medicines should not be mixed and different injection sites are to be used. Daily treatment with Ganirelix Gedeon Richter should be continued up to the day that sufficient follicles of adequate size are present. Final maturation of the egg cells in the follicles can be induced by administering human chorionic gonadotropin (hCG). The time between two injections of Ganirelix Gedeon Richter as well as the time between the last injection of Ganirelix Gedeon Richter and hCG injection should not exceed 30 hours, as otherwise a premature ovulation (i.e. release of egg cells) may occur. Therefore, when injecting Ganirelix Gedeon Richter in the morning treatment with Ganirelix Gedeon Richter should be continued throughout the gonadotropin treatment period including the day of triggering ovulation. When injecting Ganirelix Gedeon Richter in the afternoon the last injection of Ganirelix Gedeon Richter should be given in the afternoon prior to the day of triggering ovulation. Instructions for use Before the administration of this medicine it is very important that you also carefully read and closely follow the detailed instructions for use provided at the end of this package leaflet. Injection site Ganirelix Gedeon Richter is supplied in pre-filled syringes and should be injected slowly, into the fatty layer just under the skin, preferably in the upper leg. Inspect the solution before use. Do not use if the solution contains particles or is not clear. You may notice air bubble(s) in the pre-filled syringe. This is expected, and removal of the air bubble(s) is not needed. If you administer the injections yourself or have it done by your partner, follow the instructions below and at the end of the Package leaflet carefully. Do not mix Ganirelix Gedeon Richter with any other medicines. Preparing the injection site Wash your hands thoroughly with soap and water. Swab the injection site with a disinfectant (for example alcohol) to remove any surface bacteria. Clean about 5 cm (two inches) around the point where the needle will go in and let the disinfectant dry for at least one minute before proceeding. Inserting the needle Remove needle shield. Pinch a fold of skin between index finger and thumb. Insert the needle at the base of the pinched-up skin at an angle of 45° to the skin surface. Vary the injection site with each injection. Checking the correct needle position Gently draw back the plunger to check if the needle is positioned correctly. Any blood drawn into the syringe means the needle tip has penetrated a blood vessel. If this happens, do not inject Ganirelix Gedeon Richter, but remove the syringe, cover the injection site with a swab containing disinfectant and apply pressure; bleeding should stop in a minute or two. Do not use this syringe and dispose of it properly. Start again with a new syringe. Injecting the solution Once the needle has been correctly placed, push the plunger down slowly and steadily, so the solution is correctly injected and the skin tissues are not damaged. Push the plunger down until the syringe is empty and wait for 5 seconds.

3

Removing the syringe Pull the syringe out quickly and apply pressure to the site with a swab containing disinfectant. Use the pre-filled syringe only once. If you use more Ganirelix Gedeon Richter than you should Contact your doctor. If you forget to use Ganirelix Gedeon Richter If you realise that you forgot a dose, administer it as soon as possible. Do not inject a double dose to make up for a forgotten dose. If you are more than 6 hours late (so the time between two injections is longer than 30 hours) administer the dose as soon as possible and contact your doctor for further advice. If you stop using Ganirelix Gedeon Richter Do not stop using Ganirelix Gedeon Richter unless advised to by your doctor, as this may affect the outcome of your treatment. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The chance of having a side effect is described by the following categories: Very common (may affect more than 1 in 10 women) − Local skin reactions at the site of injection (predominantly redness, with or without swelling). The local reaction normally disappears within 4 hours of administration. Uncommon (may affect up to 1 in 100 women) − Headache − Nausea − Feeling generally unwell (malaise) Very rare (may affect up to 1 in 10,000 women) − Allergic reactions have been observed, as early as with the first dose.

  • Rash
  • Facial swelling
  • Difficulty breathing (dyspnoea)
  • Swelling of face, lips, tongue, and/or throat that may cause difficulty in breathing and/or swallowing (angioedema and/or anaphylaxis)
  • Hives (urticaria) − Worsening of a pre-existing rash (eczema) has been reported in one subject after the first ganirelix dose. In addition, side effects are reported which are known to occur with controlled ovarian hyperstimulation treatment (e.g. abdominal pain, ovarian hyperstimulation syndrome (OHSS), ectopic pregnancy (when the embryo develops outside the womb) and miscarriage (see the package leaflet of the FSH-containing preparation you are treated with). Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly: for United Kingdom (Northern Ireland) 4

Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store for Ireland HPRA Pharmacovigilance Website: www.hpra.ie for Malta ADR Reporting Website: www.medicinesauthority.gov.mt/adrportal By reporting side effects you can help provide more information on the safety of this medicine.

5.

How to store it

Ganirelix Gedeon Richter

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and on the carton after EXP. The expiry date refers to the last day of that month. Do not freeze. Store in the original package, in order to protect from light. Inspect the syringe before use. Use only syringes with clear, particle-free solutions and from undamaged containers. Each pre-filled syringe is only for a single use of injection. Alcohol swabs, gauze pads and sharps container are needed for administration of this medicine but they are not provided in the pack. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6.

Contents of the pack and other information

What Ganirelix Gedeon Richter contains The active substance is ganirelix (0.25 mg in 0.5 mL solution).

  • The other ingredients are: glacial acetic acid, mannitol (E 421), water for injection. The pH (measurement of the acidity) may have been adjusted with sodium hydroxide (see section 2 "Ganirelix Gedeon Richter contains sodium"). What Ganirelix Gedeon Richter looks like and contents of the pack Ganirelix Gedeon Richter is a clear and colourless solution for injection (injection). The medicine is filled in a glass syringe with staked stainless steel needle, closed with a plunger stopper and supplied with a plunger rod. The injection needle is provided with a rigid needle shield. Ganirelix Gedeon Richter is available in packs of 1 pre-filled syringe or 6 pre-filled syringes. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Gedeon Richter Plc. Gyömrői út 19-21. 5

1103 Budapest Hungary This leaflet was last revised in July 2022.

Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu

6

Instructions for use HOW TO PREPARE AND ADMINISTER GANIRELIX GEDEON RICHTER IN PREFILLED SYRINGE Before the administration of this medicine, carefully read these instructions and the package leaflet the whole way through. These instructions will help you with how to give yourself or how your partner can give you an injection of Ganirelix Gedeon Richter. If you are not sure about administering the injection or you have any questions, please ask your doctor or pharmacist for help. Do not mix Ganirelix Gedeon Richter with any other medicines. Perform the injection at the same time each day. Each pre-filled syringe contains one daily dose of ganirelix. CONTENTS OF THE INSTRUCTIONS FOR USE 1. Preparing for the injection 2. Preparing the injection site 3. Injecting the medicine 4. After the injection 1.

Preparing for the injection

•

Wash your hands thoroughly with soap and water. It is important that your hands and the items you use are as clean as possible to avoid infections. Find a clean area for the items you need for the injection, e.g. a clean table or similar horizontal surface. Gather everything you need and lay them out into the clean area:

  • Swabs containing disinfectant (e.g. alcohol)
  • 1 pre-filled syringe containing the medicine
  • Do not hold the syringe by the plunger to avoid syringe disassembling.
  • Do not use this medicine after the expiry date which is stated on the label or on the carton after EXP. The expiry date refers to the last day of that month.
  • A puncture-resistant container (e.g. a plastic bottle with a wide enough opening) to dispose the used syringe safely. Inspect the solution before use. You may notice air bubble(s) in the pre-filled syringe. This is expected, and removal of the air bubble(s) is not needed. Do not use the syringe if:
  • it is cracked or damaged, or
  • the needle shield has been removed or is not tightly attached or
  • a fluid leakage is visible or
  • the solution looks abnormal (it contains particles or it is not colourless). If any of these occurs, you should dispose the syringe safely into the sharps container and use another one.

• •

• • •

2.

Preparing the injection site

•

Choose the injection site preferably in the upper leg. The injection site should be varied for each injection to prevent the damage of tissue under the skin.

7

•

•

Do not inject yourself in any area that is tender, damaged or bruised. Always choose an intact skin area for injecting the medicine. Do not inject through clothes. Administer Ganirelix Gedeon Richter and follicle stimulating hormone (FSH) approximately at the same time. However, these medicines should not be mixed, and different injection sites are to be used. Swab the injection site with a disinfectant (for example alcohol) at the chosen injection site to remove any surface bacteria. Clean an area of about 5 cm (two inches) in diameter around the point where the needle will go in and let the disinfectant dry for about 1 minute before proceeding. Do not touch the injection site again or blow on it before the injection.

3.

Injecting the medicine

•

You receive Ganirelix Gedeon Richter in pre-filled syringes with a staked needle, ready for administration without any further adjustments to the syringe. By grabbing the middle of the syringe body, remove 1 syringe from the pack. For injecting the medicine, pull off the needle shield from the syringe that is held horizontally and pointing away from you. Do not twist but pull the needle shield off.

• •

•

• •

• •

• •

When handling the syringe, do not touch the syringe tip or the needle with your fingers to avoid contamination. At the chosen and disinfected injection site, pinch up a fold of skin between your index finger and thumb.

Administer Ganirelix Gedeon Richter subcutaneously, i.e. into the fatty layer just under the skin. Hold the syringe with your other hand so that you can place your thumb onto the plunger when 8

needed. Insert the needle completely with a quick, firm action into the middle of the pinched-up skin at an angle of 45° to the skin surface.

• •

•

Gently draw back the plunger to check if the needle is positioned correctly. Any blood drawn into the syringe means the needle tip has penetrated a blood vessel. If this happens, do not inject Ganirelix Gedeon Richter, but remove the syringe, cover the injection site with a swab containing disinfectant and apply pressure; bleeding should stop in a minute or two. Do not use this syringe and dispose of it properly and use a new syringe. Once the needle has been correctly placed, push the plunger down with your thumb slowly and steadily, so the solution is correctly injected and the skin tissues are not damaged. Push the plunger down until the syringe is empty.

4.

After the injection

• •

Wait for 5 seconds (slowly count to 5), then let go of the skin you are pinching. Pull the syringe out quickly from your skin and apply pressure to the site with a swab containing disinfectant.

• • • •

Do not rub your skin after the injection. Use each pre-filled syringe only once. Do not recap the needle to avoid needle stick injury. Discard the used syringe safely in the puncture-resistant container immediately, and return to the pharmacy for a correct disposal. Ask your pharmacist how to dispose of medicines you no longer use.

• •

9

Frequently asked questions about Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe

How do I take Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe?

Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe comes as injection containing 0.25mg / 0.5ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe?

The active substance in Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe is ganirelix.

Are there equivalent medicines to Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe?

Medicines with the same active substance, strength and form include: Fyremadel 0.25 mg/ 0.5 ml solution for injection in pre-filled syringe, Ovamex 0.25 mg/ 0.5 mL solution for injection in pre-filled syringe. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Ganirelix (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Ganirelix Gedeon Richter is indicated for the prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).

In clinical studies ganirelix was used with recombinant human follicle stimulating hormone (FSH) or corifollitropin alfa, the sustained follicle stimulant.

4.2. Posology and method of administration

Ganirelix Gedeon Richter should only be prescribed by a specialist experienced in the treatment of infertility.

Posology

Ganirelix is used to prevent premature LH surges in women undergoing COH. Controlled ovarian hyperstimulation with FSH or corifollitropin alfa may start at day 2 or 3 of menses. Ganirelix Gedeon Richter (0.25 mg) should be injected subcutaneously once daily, starting on day 5 or day 6 of FSH administration or on day 5 or day 6 following the administration of corifollitropin alfa. The starting day of ganirelix is depending on the ovarian response, i.e. the number and size of growing follicles and/or the amount of circulating oestradiol. The start of ganirelix may be delayed in absence of follicular growth, although clinical experience is based on starting ganirelix on day 5 or day 6 of stimulation.

Ganirelix and FSH should be administered approximately at the same time. However, these medicinal products should not be mixed and different injection sites are to be used.

FSH dose adjustments should be based on the number and size of growing follicles, rather than on the amount of circulating oestradiol (see section 5.1).

Daily treatment with ganirelix should be continued up to the day that sufficient follicles of adequate size are present. Final maturation of follicles can be induced by administering human chorionic gonadotropin (hCG).

Timing of last injection

Because of the half-life of ganirelix, the time between two injections of ganirelix as well as the time between the last injection of ganirelix and the hCG injection should not exceed 30 hours, as otherwise a premature LH surge may occur. Therefore, when injecting ganirelix in the morning, treatment with ganirelix should be continued throughout the gonadotropin treatment period including the day of triggering ovulation. When injecting ganirelix in the afternoon the last injection of ganirelix should be given in the afternoon prior to the day of triggering ovulation.

Ganirelix has shown to be safe and effective in women undergoing multiple treatment cycles.

The need for luteal phase support in cycles using ganirelix has not been studied. In clinical studies, luteal phase support was given according to study centres' practice or according to the clinical protocol.

Special populations

Renal impairment

There is no experience on the use of ganirelix in subjects with renal impairment, as they were excluded from clinical studies. Therefore, the use of ganirelix is contraindicated in patients with moderate or severe renal impairment (see section 4.3).

Hepatic impairment

There is no experience on the use of ganirelix in subjects with hepatic impairment, as they were excluded from clinical studies. Therefore, the use of ganirelix is contraindicated in patients with moderate or severe hepatic impairment (see section 4.3).

Paediatric population

There is no relevant use of Ganirelix Gedeon Richter in the paediatric population.

Method of administration

Ganirelix Gedeon Richter should be administered subcutaneously, preferably in the upper leg. The injection site should be varied to prevent lipoatrophy. The patient or her partner may perform the injections of Ganirelix Gedeon Richter themselves, provided that they are adequately instructed and have access to expert advice.

For instructions of the medicinal product before administration, see section 6.6 and the instructions for use included at the end of the package leaflet.

4.3. Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

- Hypersensitivity to gonadotropin-releasing hormone (GnRH) or any other GnRH analogue.

- Moderate or severe impairment of renal or hepatic function.

- Pregnancy or breast-feeding.

4.4. Special warnings and precautions for use

Hypersensitivity reaction

Special care should be taken in women with signs and symptoms of active allergic conditions. Cases of hypersensitivity reactions (both generalised and local), have been reported with ganirelix, as early as with the first dose, during post-marketing surveillance. These events have included anaphylaxis (including anaphylactic shock), angioedema and urticaria (see section 4.8). If a hypersensitivity reaction is suspected, ganirelix should be discontinued and appropriate treatment administered. In the absence of clinical experience, ganirelix treatment is not advised in women with severe allergic conditions.

Ovarian hyperstimulation syndrome (OHSS)

OHSS may occur during or following ovarian stimulation. OHSS must be considered an intrinsic risk of gonadotropin stimulation. OHSS should be treated symptomatically, e.g. with rest, intravenous infusion of electrolyte solutions or colloids and heparin.

Ectopic pregnancy

Since infertile women undergoing assisted reproduction, and particularly in vitro fertilisation (IVF), often have tubal abnormalities the incidence of ectopic pregnancies might be increased. Early ultrasound confirmation that a pregnancy is intrauterine is therefore important.

Congenital malformations

The incidence of congenital malformations after Assisted Reproductive Technologies (ART) may be higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g. maternal age, sperm characteristics) and an increased incidence of multiple gestations. In clinical studies investigating more than 1,000 new-borns it has been demonstrated that the incidence of congenital malformations in children born after COH treatment using ganirelix is comparable with that reported after COH treatment using a GnRH agonist.

Women weighing less than 50 kg or more than 90 kg

The safety and efficacy of ganirelix have not been established in women weighing less than 50 kg or more than 90 kg (see also sections 5.1 and 5.2).

Excipient

This medicinal product contains less than 1 mmol sodium (23 mg) per injection, that is to say essentially 'sodium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

The possibility of interactions with commonly used medicinal products, including histamine liberating medicinal products, cannot be excluded.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from the use of ganirelix in pregnant women.

In animals, exposure to ganirelix at the time of implantation resulted in litter resorption (see section 5.3). The relevance of these data for humans is unknown.

Breast-feeding

It is not known whether ganirelix is excreted in breast milk.

The use of Ganirelix Gedeon Richter is contraindicated during pregnancy and breast-feeding (see section 4.3).

Fertility

Ganirelix is used in the treatment of women undergoing controlled ovarian hyperstimulation in assisted reproduction programmes. Ganirelix is used to prevent premature LH surges that might otherwise occur in these women during the ovarian stimulation. For posology and method of administration, see section 4.2.

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Summary of the safety profile

The table below shows all adverse reactions in women treated with ganirelix in clinical studies using recFSH for ovarian stimulation. The adverse reactions with ganirelix using corifollitropin alfa for ovarian stimulation are expected to be similar.

Tabulated list of adverse reactions

The adverse reactions are classified according to MedDRA system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100). The frequency of hypersensitivity reactions (very rare, < 1/10,000) has been deduced from post-marketing surveillance.

System organ class

Frequency

Adverse reaction

Immune system disorders

Very rare

Hypersensitivity reactions (including rash, facial swelling, dyspnoea, anaphylaxis [including anaphylactic shock], angioedema and urticaria)1

Worsening of a pre-existing eczema2

Nervous system disorders

Uncommon

Headache

Gastrointestinal disorders

Uncommon

Nausea

General disorders and administration site conditions

Very common

Local skin reaction at the site of injection (predominantly redness, with or without swelling)3

Uncommon

Malaise

1 Cases have been reported, as early as with the first dose, among patients administered ganirelix.

2 Reported in one subject after the first ganirelix dose.

3 In clinical studies, one hour after injection, the incidence of at least once a moderate or severe local skin reaction per treatment cycle, as reported by patients, was 12% in ganirelix-treated patients and 25% in patients treated subcutaneously with a GnRH agonist. The local reactions generally disappear within 4 hours after administration.

Description of selected adverse reactions

Other reported adverse reactions are related to the controlled ovarian hyperstimulation treatment for ART, notably pelvic pain, abdominal distension, OHSS (see also section 4.4), ectopic pregnancy and spontaneous abortion.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions: via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

4.9. Overdose

Overdose in humans may result in a prolonged duration of action.

No data on acute toxicity of ganirelix in humans are available. Clinical studies with subcutaneous administration of ganirelix at single doses up to 12 mg did not show systemic adverse reactions. In acute toxicity studies in rats and monkeys, non-specific toxic symptoms such as hypotension and bradycardia were only observed after intravenous administration of ganirelix over 1 and 3 mg/kg, respectively.

In case of overdose, ganirelix treatment should be (temporarily) discontinued.

💬 Ask about this leaflet

Ask anything about Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →